Referenzen
Produkte Transfektion
Kostenlose Testsamples
Anwendungshinweise:
Im „Transfection Reagent Selection Guide“ können Sie durch Filterfunktionen z.B. für Ihre Kombination aus zu transfizierender Zelle und Nukleinsäure die Liste vorhandener Referenzen durchsuchen. Ebenso können Sie im Feld „Referenzen durchsuchen“ am Anfang der Seite mit passenden Schlagwörtern zu einem Ergebnis gelangen. Eine Referenz zeigt an, dass das gefundene Transfektionsreagenz bereits erfolgreich für die entsprechende Anwendung verwendet wurde. Im Idealfall sind getestete Transfektionsparameter und Transfektionseffizienzen angegeben.
Keine Referenz? > Allgemeine Auswahlhilfe
Wenn Sie keine Referenz gefunden haben, heißt das nicht, dass kein passendes Reagenz zur Verfügung steht, sondern lediglich, dass bisher keine Erfahrungsberichte vorliegen. In diesem Falle kann durch eine Vorauswahl ein erfolgsversprechendes Transfektionsreagenz ausgewählt (Allgemeine Auswahlhilfe) und letztendlich ausgetestet (Kostenlose Testsamples) werden. Wenn Sie einen Erfahrungsbericht für uns schreiben möchten machen wir Ihnen ein Angebot für eine Gegenleistung.
CELL TYPE | DESCRIPTION OF CELL TYPE | CAT.NO. | SPECIES | ORIGIN OF CELLS | COMMON CELL TYPE | GROWTH PROPERTIES | NUCLEIC ACID / DELIVERED MOLECULE | APPLICATION | PRODUCT | REFERENCE TYPE | BIBLIOGRAPHIC DATA | LINK | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | W. Kim et al., J. Biol. Chem., 287 (8): 5278–5289, DOI 10.1074/jbc.M111.281709 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | D. Marotta, PhD Thesis, 2015, University College London | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | M. M. Nalaskowski et al., J. Biol. Chem., Feb 2011; 286: 4500 - 4510 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | RNA-Interference | Metafectene EASY | publication | M. De Luca et al., J. Cell Sci., Jun 2014; 127: 2697 - 2708 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | E. Pesarchuk, 2016, Dissertation, Universtity of Vancouver | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | cotransfection (plasmid/plasmid) | K2 Transfection System | application note | ![]() |
||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | R. Berro et al., J. Virol., Apr 2006; 80: 3189 - 3204 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene PRO | publication | L. Najmi, PhD Thesis, 2018, University of Bergen | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | miRNA | Metafectene PRO | publication | S. Demir, Master Thesis, 2012, Izmir Institute of Technology | |||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | S. W. Lee et al., EMBO J., Nov 2012; 31: 4441 - 4452 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | plasmid | Metafectene | publication | N. Cidlinsky et al., Cell Oncol., 2016, 39:389-396; DOI 10.1007/s13402-016-0290-8 | ||||
HeLa CIITA |
Human cervix adenocarcinoma cell line, stably expressing the MHC class II transactivator CIITA | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | M. Schindler et al., J. Virol., Oct 2003; 77: 10548 - 10556 | Link | |||
HeLa CIITA |
Human cervix adenocarcinoma cell line, stably expressing the MHC class II transactivator CIITA | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | J. Münch et al., J. Virol., Aug 2005, 79 (16), 10547-10560 | Link | |||
HeLa CIITA |
Human cervix adenocarcinoma cell line, stably expressing the MHC class II transactivator CIITA | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | F. Kirchhoff et al., J. Virol., Jul 2004; 78: 6864 - 6874. | Link | |||
HeLa CIITA |
Human cervix adenocarcinoma cell line, stably expressing the MHC class II transactivator CIITA | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | M. Brenner et al., J. Virol., May 2006; 80: 4469 - 4481 | Link | |||
HeLa CIITA |
Human cervix adenocarcinoma cell line, stably expressing the MHC class II transactivator CIITA | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | M. Schindler et al., J. Virol., Oct 2004; 78: 10588 - 10597 | Link | |||
HeLa-229 |
Human cervix adenocarcinoma cell line (derivat of HeLa) | ATCC CCL-2.1 | Human | genital tract | cell line | adherent | plasmid | K2 Transfection System | application note | ![]() |
|||
HeLa-229 |
Human cervix adenocarcinoma cell line (derivat of HeLa) | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | K2 Transfection System | publication | D. Kaul et al., Blood Cells, Molecules and Diseases, 2015, 55: 89-93, doi.org/10.1016/j.bcmd.2015.05.001 | |||
HeLa-229 |
Human cervix adenocarcinoma cell line (derivat of HeLa) | Human | genital tract | cell line | adherent | plasmid | K2 Transfection System | publication | A. Garg et al., Blood Cells, Molecules and Diseases, 2015, 55: 248-254, doi.org/10.1016/j.bcmd.2015.07.009 | ||||
HeLa-229 |
Human cervix adenocarcinoma cell line (derivat of HeLa) | Human | genital tract | cell line | adherent | plasmid | K2 Transfection System | publication | D. Kaul et al., Blood Cells, Molecules and Diseases, 2015, 55: 89-93, doi.org/10.1016/j.bcmd.2015.05.001 | ||||
HeLa-ABCA1-GFP |
Human cervix adenocarcinoma cell line (derivat of HeLa) | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | N. Mukhamedova et al., Methods Mol. Biol., 2016 ; 1354: 281-292; doi:10.1007/978-1-4939-3046-3_19 | ||||
HeLa-DR-13–9 |
Human cervix adenocarcinoma cell line (derivative of HeLa) | Human | genital tract | cell line | adherent | plasmid | RNA-Interference | Metafectene | publication | B. Haynesa et al., Biochim Biophys Acta Mol Basis Dis., 2020,1866(1): 165561, doi:10.1016/j.bbadis | Link | ||
HeLa-eGFP |
Human cervix adenocarcinoma cell line, stably expressing eGFP (derivat of HeLa) | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | P. del Pino et al., Nano Lett, Oct 2010; 10(10): 3914-21 | |||
HeLa-fLuc |
Human cervix adenocarcinoma cell line, stably expressing Firefly-Luciferase (derivat of HeLa) | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | P. del Pino et al., Nano Lett, Oct 2010; 10(10): 3914-21 | |||
HeLa-S3 |
Human cervix carcinoma cell line (subclone) | ATCC CCL-2.2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | application note | ![]() |